Vireo Growth
Cannabis operator with dispensaries and cultivation across multiple US states.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Vireo Growth earns a Neutral rating, with a 57.5 composite score and 2/5 conviction. Fundamentals provide the decisive support at 88, led by top-tier revenue growth, an 82.7 gross-margin subscore, an 89.7 operating-margin subscore, and a 90 cash-runway subscore reflecting positive EBITDA alongside a net loss. Regulatory contributes a middling 49, combining a 50 jurisdiction posture and 80 enforcement subscore with a weak 25 cadence subscore. Market contributes 40 because no institutional quote is available, while editorial contributes 30 amid no recent newsroom or brief activity. The resulting profile places Vireo firmly in the Neutral band: operating performance is strong, but regulatory cadence, market visibility, and editorial momentum dilute conviction.
Licensed fundamentals data show year-over-year revenue growth above 330%, a gross margin just under 50%, and an operating margin near 17%. Those figures explain the fundamentals pillar’s clear lead and indicate substantial operating leverage. EBITDA stands near $45 million, but net income remains a loss of roughly $82 million, preserving the stretched financial condition despite positive operating earnings. Market capitalization is approximately $491 million. Primary regulatory filings show no events during the latest 90-day period and only one during the latest 180-day period, with the most recent filing dated June 18, 2026. The absence of enforcement hits supports the regulatory pillar, but sparse filing activity constrains its overall contribution. Institutional pricing feeds provide no current quote, and CIN newsroom coverage records no newsroom or brief hits, leaving both market and editorial pillars without incremental support.
The forward case rests on fundamentals converting exceptional revenue growth and strong margins into improved bottom-line performance. Positive EBITDA already demonstrates operating earnings capacity, while the near-50% gross margin and high-teens operating margin provide the strongest basis for further earnings conversion. A sustained reduction in the roughly $82 million net loss would strengthen the leading pillar, improve the stretched financial profile, and create the clearest route above Neutral. The single most important signal to watch is whether the next primary regulatory filing shows that strong revenue growth and operating margins are translating into a materially narrower net loss.
- IR email
- investor@vireogrowth.com
- IR page
- Investor relations
- Headquarters
- 207 SOUTH 9TH STREET, MINNEAPOLIS, MN, 55402
- Phone
- 604-617-5421
- CEO
- John Mazarakis
- CFO
- Tyson Macdonald
- SEC CIK
- 1771706
- Website
- Company website
- Market cap
- $490.7M
- Enterprise value
- $769.4M
- Price to book
- 1.67
- Price to sales
- 1.40
- EV / EBITDA
- 40.49
- Revenue (TTM)
- $350.5M
- Gross profit (TTM)
- $174.0M
- EBITDA
- $45.2M
- Operating margin
- 16.7%
- Profit margin
- -23.4%
- Rev growth YoY
- 333.5%
- Return on equity
- -47.5%
- Return on assets
- 2.6%
- EPS (TTM)
- $-2.70
- EPS est. current year
- $0.20
- Wall St. target price
- $45.00
- Shares outstanding
- 48.5M
- Insider ownership
- 33.2%
- Institutional ownership
- 7.8%
- Beta
- 0.07
- Full-time employees
- 520
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Vireo Growth (VREOF)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Vireo Growth (VREOF), a cannabis-sector equity listed on OTCMKTS in the US MSO category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (3 bullish signals, 1 bearish signal.)
Cannabis operator with dispensaries and cultivation across multiple US states.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for VREOF are maintained by Cannabis Investor News and refreshed throughout the trading day.